ID   CTSC#393
AC   CVCL_A9WP
SY   CRC-SC#393; CSC11
DR   cancercelllines; CVCL_A9WP
DR   Wikidata; Q102113741
RX   PubMed=26956206;
RX   PubMed=27286453;
RX   PubMed=33128777;
CC   Group: Cancer stem cell line.
CC   From: Sant Andrea Hospital; Rome; Italy.
CC   Microsatellite instability: Stable (MSS) (PubMed=33128777).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ala440Thr (c.1318G>A); ClinVar=VCV000418008; Zygosity=Unspecified (PubMed=33128777).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ala759Asnfs*2 (c.2273_2285delAAGCCCTAGAAGC); Zygosity=Unspecified (PubMed=33128777).
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Val325Ile (c.973G>A); Zygosity=Unspecified (PubMed=33128777).
CC   Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Glu110Lys (c.328G>A); Zygosity=Unspecified (PubMed=33128777).
CC   Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Gln277Ter (c.829C>T); Zygosity=Unspecified (PubMed=33128777).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu453Lys (c.1357G>A); ClinVar=VCV000376470; Zygosity=Unspecified (PubMed=33128777).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu970Val (c.2909A>T); Zygosity=Unspecified (PubMed=33128777).
CC   Derived from site: In situ; Colon, proximal; UBERON=UBERON_0008972.
ST   Source(s): PubMed=33128777
ST   Amelogenin: X,Y
ST   CSF1PO: 13
ST   D13S317: 9,12
ST   D16S539: 9
ST   D5S818: 12
ST   D7S820: 12
ST   TH01: 7,9
ST   TPOX: 8,11
ST   vWA: 18
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   57Y
CA   Cancer cell line
DT   Created: 29-10-20; Last updated: 05-10-23; Version: 7
//
RX   PubMed=26956206; DOI=10.5966/sctm.2015-0214;
RA   De Angelis M.L., Zeuner A., Policicchio E., Russo G., Bruselles A.,
RA   Signore M., Vitale S., De Luca G., Pilozzi E., Boe A., Stassi G.,
RA   Ricci-Vitiani L., Amoreo C.A., Pagliuca A., Francescangeli F.,
RA   Tartaglia M., De Maria R., Baiocchi M.;
RT   "Cancer stem cell-based models of colorectal cancer reveal molecular
RT   determinants of therapy resistance.";
RL   Stem Cells Transl. Med. 5:511-523(2016).
//
RX   PubMed=27286453; DOI=10.18632/oncotarget.9859;
RA   Signore M., Buccarelli M., Pilozzi E., De Luca G., Cappellari M.,
RA   Fanciulli M., Goeman F., Melucci E., Biffoni M., Ricci-Vitiani L.;
RT   "UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer
RT   stem-like cells by impairing DNA damage response.";
RL   Oncotarget 7:44113-44128(2016).
//
RX   PubMed=33128777; DOI=10.1002/ijc.33370;
RA   Visconti P., Parodi F., Parodi B., Casarino L., Romano P.,
RA   Buccarelli M., Pallini R., D'Alessandris Q.G., Montori A., Pilozzi E.,
RA   Ricci-Vitiani L.;
RT   "Short tandem repeat profiling for the authentication of cancer
RT   stem-like cells.";
RL   Int. J. Cancer 148:1489-1498(2021).
//